Literature DB >> 21654725

Gene and genetic diagnostic method patent claims: a comparison under current European and US patent law.

Isabelle Huys1, Geertrui Van Overwalle, Gert Matthijs.   

Abstract

The paper focuses on the fundamental debate that is going on in Europe and the United States about whether genes and genetic diagnostic methods are to be regarded as inventions or subject matter eligible for patent protection, or whether they are discoveries or principles of nature and thus excluded from patentability. The study further explores some possible scenarios of American influences on European patent applications with respect to genetic diagnostic methods. Our analysis points out that patent eligibility for genes and genetic diagnostic methods, as discussed in the United States in the Association of Molecular Pathology versus US Patent and Trademark Office decision, is based on a different reasoning compared with the European Patent Convention.

Mesh:

Substances:

Year:  2011        PMID: 21654725      PMCID: PMC3190248          DOI: 10.1038/ejhg.2011.76

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  8 in total

1.  European-wide opposition against the breast cancer gene patents.

Authors:  Gert Matthijs; Dicky Halley
Journal:  Eur J Hum Genet       Date:  2002-12       Impact factor: 4.246

2.  Gene patenting--is the pendulum swinging back?

Authors:  Aaron S Kesselheim; Michelle M Mello
Journal:  N Engl J Med       Date:  2010-04-07       Impact factor: 91.245

3.  Introduction.

Authors:  Gert Matthijs; Ségolène Aymé
Journal:  Eur J Hum Genet       Date:  2008-05       Impact factor: 4.246

4.  Legal uncertainty in the area of genetic diagnostic testing.

Authors:  Isabelle Huys; Nele Berthels; Gert Matthijs; Geertrui Van Overwalle
Journal:  Nat Biotechnol       Date:  2009-10       Impact factor: 54.908

5.  Patenting biotech beyond the central dogma.

Authors:  George Wu
Journal:  Nat Biotechnol       Date:  2010-03       Impact factor: 54.908

Review 6.  The European opposition against the BRCA gene patents.

Authors:  Gert Matthijs
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

7.  American College of Medical Genetics position statement on gene patents and accessibility of gene testing.

Authors: 
Journal:  Genet Med       Date:  1999 Jul-Aug       Impact factor: 8.822

8.  Gene patents and personalized medicine - what lies ahead?

Authors:  Subhashini Chandrasekharan; Robert Cook-Deegan
Journal:  Genome Med       Date:  2009-09-28       Impact factor: 11.117

  8 in total
  3 in total

1.  Biomarker patents for diagnostics: problem or solution?

Authors:  Michael M Hopkins; Stuart Hogarth
Journal:  Nat Biotechnol       Date:  2012-06-07       Impact factor: 54.908

2.  The European BRCA patent oppositions and appeals: coloring inside the lines.

Authors:  Gert Matthijs; Isabelle Huys; Geertrui Van Overwalle; Dominique Stoppa-Lyonnet
Journal:  Nat Biotechnol       Date:  2013-08       Impact factor: 54.908

3.  Gene patents in the US--focusing on what really matters.

Authors:  Allison W Dobson; James P Evans
Journal:  Genome Biol       Date:  2012-06-29       Impact factor: 13.583

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.